A Phase 2 Clinical Trial to Evaluate the Safety, Clinical Effects, and Systemic Exposure of a Topical Application of BMX-010 Ointment in Adult Subjects With Atopic Dermatitis
Latest Information Update: 23 Apr 2024
At a glance
- Drugs BMX-010 (Primary)
- Indications Atopic dermatitis
- Focus Adverse reactions; Therapeutic Use
- Sponsors BioMimetix
Most Recent Events
- 17 Apr 2024 Status changed from active, no longer recruiting to discontinued due to funding constraints.
- 11 Sep 2023 Status changed from recruiting to active, no longer recruiting.
- 04 May 2023 Status changed from active, no longer recruiting to recruiting.